Page 1

Exhibit 99.3 ADC THERAPEUTICS ADC Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates Encouraging initial launch of ZYNLONTA TM ( loncastuximab tesirine - lpyl ) driven by favorable product profile to address high unmet medical need in relapsed / refractory DLBCL market - Company to host conference call today at 8:30 a.m. EDT Lausanne , Switzerland , August 3 , 2021 - ADC Therapeutics SA ( NYSE : ADCT ) , a commercial - stage biotechnology company improving the lives of those affected by cancer with its next - generation , targeted antibody drug conjugates ( ADCs ) for patients with hematologic malignancies and solid tumors , today reported financial results for the second quarter ended June 30 , 2021 and provided business updates . " We were thrilled to receive accelerated FDA approval for the first indication for ZYNLONTA ™ and are encouraged by the momentum and positive feedback in the initial weeks following approval . We remain highly focused on the successful execution of the launch and positive about the longer - term potential of the product , " said Chris Martin , Chief Executive Officer of ADC Therapeutics . " During the second quarter , we were also pleased to present positive data on ZYNLONTA and our exciting pipeline of advancing programs at key medical meetings . Looking to the rest of the year , we have several notable milestones on the horizon and look forward to keeping you updated on our progress . " Recent Highlights and Developments ZYNLONTA ( loncastuximab tesirine - lpyl ) • Launch update : о о о ZYNLONTA generated net sales of $ 3.8 million for the two - month period following accelerated U.S. Food and Drug Administration ( FDA ) approval on April 23 , 2021 , reflecting patient demand with no material inventory build . Launch performance was driven by the differentiated profile of ZYNLONTA in addressing an area of high unmet medical need . The Company has engaged prioritized accounts , with patient starts at a significant percentage of key accounts . A substantial number of the National Comprehensive Cancer Network ( NCCN ) centers have ordered and reordered ZYNLONTA . There has been positive reception across the treatment site spectrum from academic- to community - based centers reflecting the broad applicability of ZYNLONTA in the 3L + setting supported by the LOTIS - 2 pivotal data . ZYNLONTA was added to the NCCN Guidelines with a Category 2A recommendation just two weeks after receiving accelerated FDA approval . The NCCN guidelines listing is consistent with the broad FDA - approved indication . As a result , payer access and medical policy publication have accelerated . The Company is pleased with the positive launch momentum in a continuing COVID environment . The sales and medical teams are executing with a hybrid model , and there has been an increase in face - to - face visits .